Description:
NIEMANN-PICK DISEASE, TYPE C1; NPC1
NPC1 GENE; NPC1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
16 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase,Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
Gene |
NPC1 |
Chromosomal Location |
18q11-q12 |
Allelic Variant 1 |
; NIEMANN-PICK DISEASE, TYPE C1 |
Identified Mutation |
451_452delAG |
|
Gene |
NPC1 |
Chromosomal Location |
18q11-q12 |
Allelic Variant 2 |
Y825C; NIEMANN-PICK DISEASE, TYPE C1 |
Identified Mutation |
TYR825CYS |
Remarks |
Clinically affected; diagnosed at age 21 yr; deceased at 32 yr; family history of NPC; clumsy; learning difficulties; ataxia; vertical gaze palsy; dysarthria; dysphagia; psychiatric disorder; absence of communication; difficulty with movement; constant difficulty swallowing; fibroblasts showed 10 pmol CE/mg protein/6 hr activity in a cholesterol esterification assay [normal mean was 1855 +/- 1327 pmol CE/mg protein/6 hr, see Park et al. Hum Mut 22:313-325 (2003)]; fibroblasts were scored as npc-like in a filipin staining assay (see Park et al., 2003); a complementation test showed that the cells were of the type 1 complementation group (see Park et al., 2003); the donor subject is a compound heterozygote at the NPC1 gene locus: allele 1 carries a 2 bp deletion mutation (delAG) at nucleotide 451 (c.451_452delAG; 451delAG) in exon 4; allele 2 carries a substitution of A>G at nucleotide 2474 (c.2474A>G) in exon 16, resulting in a missense mutation at codon 825 [Y825C (TYR825CYS)]; the subject also carries the following polymorphism: A>G at nucleotide 644 (c.644A>G) resulting in the substitution of arginine for histidine (H>R) at codon 215 [H215R (HIS215ARG)]; the first nucleotide of the initiating Met codon is numbered +1. |
Pepponi R, De Simone R, De Nuccio C, Visentin S, Matteucci A, Bernardo A, Popoli P, Ferrante A, Repurposing Dipyridamole in Niemann Pick Type C Disease: A Proof of Concept Study International journal of molecular sciences23: 2022 |
PubMed ID: 35408815 |
|
Schultz ML, Krus KL, Kaushik S, Dang D, Chopra R, Qi L, Shakkottai VG, Cuervo AM, Lieberman AP, Coordinate regulation of mutant NPC1 degradation by selective ER autophagy and MARCH6-dependent ERAD Nature communications9:3671 2017 |
PubMed ID: 30202070 |
|
Visentin S, De Nuccio C, Bernardo A, Pepponi R, Ferrante A, Minghetti L, Popoli P, The stimulation of adenosine A2A receptors ameliorates the pathological phenotype of fibroblasts from Niemann-Pick type C patients The Journal of neuroscience : the official journal of the Society for Neuroscience33:15388-93 2013 |
PubMed ID: 24068806 |
|
Park WD, O'Brien JF, Lundquist PA, Kraft DL, Vockley CW, Karnes PS, Patterson MC, Snow K, Identification of 58 novel mutations in Niemann-Pick disease type C: Correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum Mutat22(4):313-25 2003 |
PubMed ID: 12955717 |
Passage Frozen |
16 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
3% |
Medium |
Eagles Minimum Essential Medium with Earle's salts:Dulbecco's modified MEM with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
None specified |
Subcultivation Method |
trypsin-EDTA |
Supplement |
- |
|
|